COI Disclosure Information I have no financial relationships

COI Disclosure Information Ｙｕｔａｋａ　Ｋａｗａｋａｍｉ 　 I have no financial relationships to disclose related to this presentation.

Conflict of Interest in publication ethics （Authors, Reviewers, Editors, Publishers) ・Financial COI 　 Financial relationship 　　advisory role, stock ownership, patent royalty, honoraria, research finding, manuscript fee, etc ・Non-financial COI 　Any non-financial support from industries 　　Drug supply, support for data analysis, paper writing, etc. 　　In paper review process, personal relationship, direct academic competition, etc. ・Publication bias / reporting bias ・ Medical journal for drug promotion?

JAMA, 303(23): 2400 -2402, 2010 ・As the nation's biomedical research agency, the National Institutes of Health (NIH) must ensure that the research it funds on the behalf of US taxpayers is scientifically rigorous and free of bias. Americans do not want financial conflicts of interest (FCOI) to influence the federally funded research they hope will yield better ways to fight disease and improve health. ・If NIH-supported researchers fail to disclose the full extent of their financial interests, universities fail to comprehensively manage FCOI, or NIH fails to diligently oversee the entire system, public trust will be jeopardized in ways that may have farreaching implications for the future of science. NIH COI管 理 指 導 COI申告 研究者 COI管 理 研究施設 学会 学術雑誌

ASCO(米国臨床腫瘍学会)のCOIポリシー 1996, 2002, 2005, 2013 (2014) Information to be disclosed ・Compensation received for employment, leadership positions, consulting activities, speaking engagements, and expert testimony ・Ownership interests ・Research funding to the individual or institution ・Licensing fees & royalties associated with intellectual property interests ・Other remuneration 2013 Author restriction (1 st, last, corresponding) 　(general disclosure) 1) speakers’ bureau, 2) employment, 3) significant ownership interest (>$50, 000) during the 2 years before submission (Exemption: Research funded by NIH) 2014 ASCO suspended the author restriction for 3 years to evaluate it.

Cancer Science COI Policy The Japanese Cancer Association (JCA) requires authors, editors and reviewers, to disclose any potential conflict of interest related to articles submitted for publication in “Cancer Science”. A conflict of interest exists when anyone has financial or personal relationships that could inappropriately influence (bias) toward his or her actions. The intent of the JCA Conflict of Interest disclosure policy is to provide authors, editors, and readers with all the facts necessary to make informed judgments about the content of Cancer Science. All authors will be required to complete a conflict of interest form as part of the manuscript submission process. The corresponding author is responsible for obtaining completed forms from all authors of the manuscript. The disclosure of a potential conflict of interest does not necessarily affect the manuscript’s chances of acceptance. Disclosures, only when clearly related to the topic of the present manuscript, will appear as “Disclosure Statement” in published article. Disclosures that the author deems relevant will be disclosed publicly. Serious failure by any author to disclose a conflict that later comes to light will result in a ban on the author publishing in Cancer Science for a period of maximum 3 years. Editors and Associate Editors are required to fill out conflict of interest forms on an annual basis. Editors, Associate Editors and persons asked to peer review a manuscript, should voluntarily remove themselves from involvement in any manuscript review or discussion if they believe they could have a conflict of interest.

COI Disclosure for Cancer Science Financial COI ・Employment/Leadership position/ Advisory role (1, 000 yen / US$10, 000 or more) ・Stock ownership (Profit of 1, 000 yen / US$10, 000 or more/ownership of 5% or more of total shares) ・Patent royalties/licensing fees (1, 000 yen / US$10, 000 or more) ・Honoraria (e. g. lecture fees) (500, 000 yen /US$5, 000 or more) ・Fees for promotional materials (e. g. manuscript fee) (500, 000 yen /US$5, 000 or more) ・Research funding (2, 000 yen /US$20, 000 or more) ・Others (e. g. trips, travel, or gifts, which are not related to research) (50, 000 yen /US$500 or more) For clinical studies If your paper is regarding a clinical study, you should also disclose the following： ・Clinical study conducted/led by an Industry (when an industry is responsible for the study). ・Funding (applicable regardless of amount) ・Supply of drugs for experiments ・Support provided to collect/analyze data or to write a manuscript